Introduction
============

Spontaneous preterm birth (SPB) is a major cause of neonatal mortality and morbidity. In 2016, preterm births accounted for 9.85% of all births in the United States of America. Preterm birth accounted for 59.91% of all twin births versus 8.02% of all singleton births \[[@B1]\]. One of the best methods for predicting SPB is the assessment of the cervical length (CL) on second-trimester transvaginal sonography \[[@B2][@B3][@B4][@B5]\].

The interventions known to be effective for preventing SPB in singleton pregnancies include bed rest, prophylactic cervical cerclage, and progesterone supplementation \[[@B6][@B7]\]. Unfortunately, none of these interventions is effective for high-risk twin pregnancies \[[@B8][@B9][@B10]\]. Cervical pessaries, which have not been widely used in Korea, have been investigated for their ability to reduce preterm birth rates. For centuries, vaginal pessaries have been used for vaginal prolapse. Many gynecologists have used pessaries due to fitting and management convenience. In 1959, Cross reported using a ring pessary to treat cervical laceration, cervical incompetence, or uterus didelphys \[[@B11]\], and some physicians attempted the use of pessaries for prophylaxis of SPB. In the late 1970s, Hans Arabin designed a dome-shaped, flexible silicone pessary \[[@B12]\]. The Arabin pessary supports the cervix and consequently prevents opening of the internal os, changes the uterocervical angle to shift the uterine weight toward the lower anterior segment rather than directly on the cervix, and protects the cervical mucus plug, which acts as a protective film to prevent infection \[[@B13]\]. Several studies have investigated the effectiveness of cervical pessaries in twin pregnancies; however, the conclusions remain controversial. Our study aimed to evaluate cervical pessaries as an option for preventing SPB in twin pregnancies among women with a short cervix.

Materials and methods
=====================

Women with twin pregnancies at 16--28 weeks of gestation were included. All women underwent transvaginal ultrasonography with an empty bladder. A CL of ≤15 mm was considered short. We reviewed the charts of all patients with a twin pregnancy between January 2014 and March 2019. We included women with a shortened CL after a cerclage procedure and visible fetal membranes with cervical dilatation. Three of our patients had membrane bulging and one patient in the pessary group underwent amnioreduction of 120 mL because of protruding membranes. We excluded women with major fetal anomalies discovered before or after birth and known placenta previa. Since 2016, patients were informed of the potential advantages, and pessaries were placed only in those who agreed to participate. The use of a cervical pessary for prophylaxis of SPB is not approved by the Korean Food and Drug Administration. All patients were informed of its use, and written informed consent was obtained prior to insertion. The study was approved by the Institutional Review Board (IRB) and Ethics Committee of Gachon University Gil Medical Center (IRB number GCIRB2018-198) and performed in accordance with the principles of the Declaration of Helsinki. All patients were prescribed 200 mg of vaginal progesterone daily. Study patients with a short cervix underwent Arabin pessary placement (ARABIN^®^ Cerclage Pessary by Dr. Arabin, GmbH & Co. KG, Witten, Germany); controls with a short cervix did not undergo pessary placement. Women in both groups were prescribed antibiotics if the C-reactive protein (CRP) level was higher than normal or when inflammation was suspected. When no signs of inflammation were apparent and the CRP level was acceptable, the pessaries were inserted. A flexible ring-like silicone Arabin pessary was offered in the pessary group, which is inexpensive and can be non-invasively and easily placed and removed without anesthesia \[[@B14]\]. After taking cervical swabs, the operator unfolded and placed a pessary around the cervix, with the small ring toward the cervix and the large ring toward the pelvic floor, and then pressed it slightly toward the sacrum. If the cervical swab detected bacteria, patients were treated with appropriate antibiotics. The pessary was sized according to the instructions provided by Arabin and Alfirevic after measuring the cervix on transvaginal sonography and performing pelvic examination using a speculum \[[@B14]\]. Pessary removal should be performed before the onset of delivery or at around 37 weeks. The pessary can be removed easily without the use of any instrument. Arabin and Alfirevic advised pushing the cervix back through the inner ring of the pessary \[[@B14]\]. In our study, the pessary was removed at 36 weeks in one patient prior to vaginal delivery and immediately before or after cesarean section in the other patients. In all treated patients, CL was measured via transvaginal sonography before and after pessary insertion. [Fig. 1](#F1){ref-type="fig"} shows the sonographs after pessary insertion according to the new transvaginal technique provided by Goya et al. \[[@B15]\], in which the transvaginal probe is inserted to the pessary to touch the anterior cervical lip. Continuous variables were compared using Student\'s *t*-test or the Mann-Whitney *U*-test. Categorical variables were evaluated using Pearson\'s χ^2^ test or Fisher\'s exact test. The risk of preterm birth was quantified as odds ratios and 95% confidence intervals (CIs) using logistic regression. The probability of continued pregnancy was assessed using Kaplan-Meier analysis ([Fig. 2](#F2){ref-type="fig"}), in which delivery at \<34 weeks was the outcome. IBM^®^ SPSS^®^ Statistics version 22 (SPSS Inc., Chicago, IL, USA) was used for the statistical analysis, and *P*\<0.05 were considered significant.

![Transvaginal sonographs showing cervical length after pessary insertion.](ogs-63-231-g001){#F1}

![Kaplan-Meier curves of probability of continued pregnancy.](ogs-63-231-g002){#F2}

Results
=======

Nineteen women were initially included in the study. Six were excluded from the analysis because of loss to follow-up or insufficient data. Therefore, 13 women with a CL of ≤15 mm underwent pessary placement and 15 women with a CL of ≤15 mm were considered controls and did not receive pessary placement. Baseline CL values (0.65±0.47 vs. 0.66±0.51 cm in the treatment and control groups, respectively; *P=*0.957) and gestational ages (23.29 vs. 25.14 weeks; *P=*0.294) were similar between the groups. The other characteristics are described in [Table 1](#T1){ref-type="table"}. There was no significant preterm history in either group. Three women in the pessary group and four in the control group were multigravidas. One patient in each group underwent a biopsy using a loop electrosurgical excision procedure (LEEP). Of the six patients who received a cerclage in the pessary group, two underwent the procedure at other clinics. Of the five patients who received cerclage in the control group, three underwent the procedure at a local clinic. Four patients in the pessary group and two in the control group received rescue cerclage in our hospital prior to the pessary insertion. Dichorionic twins were more common in the pessary group than in the control group because three-fourth of women in the pessary group became pregnant through *in vitro* fertilization (IVF). There was no significant difference in the initial hemoglobin level, white blood cell count, or CRP level between the two groups. The mean CL after pessary insertion increased by approximately 1.68±0.78 cm. Pessary insertion was performed at a median gestational age of 24.29 weeks. In some women, it took several days to prepare for pessary insertion. The length of hospital stays ranged from 2 to 97 days for patients who received pessary placement, with a median of 11 days.

###### Characteristics of the study participants

![](ogs-63-231-i001)

  Characteristic                                 Pessary (n=13)       Control (n=15)       *P*-value   
  ---------------------------------------------- -------------------- -------------------- ----------- -------
  Age (yr)                                       32.92±2.78           32.80±2.40           0.641       
  Height (cm)                                    161.54±5.64          161.67±6.26          0.955       
  Weight (kg)                                    68.77±13.40          65.20±10.69          0.440       
  BMI (kg/m^2^)                                  26.24±4.21           24.88±3.38           0.352       
  IVF                                            10 (76.9)            5 (33.3)             0.030       
  Cerclage op                                    6 (46.2)             5 (33.3)             0.488       
  Chorionicity                                                                                         
                                                 Dichorionic          13 (100.0)           8 (53.3)    0.007
                                                 Monochorionic        0 (0.0)              7 (46.7)    0.007
  Initial CRP (mg/dL)                            0.91±1.60            1.18±1.60            0.369       
  Initial Hb (g/dL)                              10.97±1.29           11.07±1.33           0.836       
  Initial WBC (/mm^3^)                           10,860.77±3,032.21   10,376.67±2,236.40   0.632       
  Gestational age at randomization (wk)          23.29 (20.5--26.0)   25.14 (21.9--26.4)   0.294       
  Initial cervical length (cm)                   0.65±0.47            0.66±0.51            0.957       
  Cervical length after pessary insertion (cm)   1.68±0.78            \-                               
  Gestational age at pessary insertion (wk)      24.29 (22.1--26.1)   \-                               
  Admission days after pessary insertion (day)   11 (4--25.5)         \-                               

Data are presented as numbers (percentages), means±standard deviations, or medians (interquartile ranges).

IVF, *in vitro* fertilization; CRP, C-reactive protein; Hb, hemoglobin; WBC, white blood cell.

Pregnancy outcomes are shown in [Table 2](#T2){ref-type="table"}. The median gestational age at delivery in the pessary group was higher than that in the control group (33.29 vs. 27.29 weeks, respectively; *P*=0.058). One woman who underwent pessary placement had a term birth at 37.4 weeks of gestation; however, none of the patients in the control group had given birth at ≥37 weeks. A cervical pessary can help significantly prolong the time to delivery (60.69±28.26 vs. 22.60±24.45 days; *P*=0.001). Analysis of covariance controlling for the difference at baseline (IVF and chorionicity) showed that the mean gestational age at delivery was 32.07±1.46 weeks in the pessary group and 27.16±1.34 weeks in the control group (adjusted *P*=0.032) and that the time from randomization to delivery was significantly different between the groups (60.38±8.4 vs. 22.87±7.7 days; adjusted *P*=0.006). The use of a cervical pessary tended to reduce preterm birth at \<32 weeks; however, the difference was not significant (38.5% vs. 73.3%, odds ratio, 0.227; 95% CI, 0.046--1.125; *P*=0.069). [Fig. 1](#F1){ref-type="fig"} shows the Kaplan-Meier analysis of the cumulative percentage of patients who did not give birth before 34 weeks, where gestational age was the time scale and all pregnancies were considered no longer at risk for any event at the start of the 34th week. The probability of continued pregnancy did not differ between the groups (log-rank, *P*=0.063).

###### Pregnancy outcomes
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  Pregnancy outcome                  Pessary (n=13)         Control (n=15)       Odds ratio (95% CI)   *P*-value              
  ---------------------------------- ---------------------- -------------------- --------------------- ---------------------- -------
  Gestational age at delivery (wk)   33.29 (26.4--34.8)     27.29 (25.1--32.9)   \-                    0.058                  
  Days to delivery (day)             60.69±28.26            22.60±24.45          \-                    0.001                  
  Preterm birth                                                                                                               
                                     \>24 wk of gestation   1 (7.7)              3 (20.0)              0.333 (0.030--3.676)   0.370
                                     \>28 wk of gestation   4 (30.8)             8 (53.3)              0.389 (0.082--1.840)   0.234
                                     \>32 wk of gestation   5 (38.5)             11 (73.3)             0.227 (0.046--1.125)   0.069
                                     \>34 wk of gestation   8 (61.5)             13 (86.7)             0.246 (0.038--1.583)   0.140

Data are presented as numbers (percentages), means±standard deviations, or medians (interquartile ranges).

CI, confidence interval.

One woman in the pessary group had a stillbirth at 23.4 weeks, and six in the control group had a stillbirth before 22 weeks. The use of a cervical pessary was associated with a higher birth weight, particularly fewer neonates with a birth weight of \<1,500 or \<1,000 g ([Table 3](#T3){ref-type="table"}).

###### Perinatal outcomes
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  Perinatal outcome   Pessary (n=26)    Control (n=30)    *P*-value   
  ------------------- ----------------- ----------------- ----------- -------
  Birth weight (g)    1,687.88±731.91   1,074.67±625.52   0.001       
                      \<1,000           6 (23.1)          17 (56.7)   0.011
                      \<1,500           8 (30.8)          24 (80)     0.000
                      \<2,500           23 (88.5)         30 (100)    0.094
  Fetal death         1 (3.8)           6 (20)            0.108       

Data are presented as numbers (percentages) or means±standard deviations.

Neonatal intensive care unit admission was required for 84% of neonates in the pessary group versus all of those in the control group. The rates of adverse neonatal outcomes in the pessary group were significantly different from those in the control group ([Table 4](#T4){ref-type="table"}).

###### Neonatal outcomes
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  Neonatal outcome           Pessary (n=25)                  Control (n=24)   *P*-value   
  -------------------------- ------------------------------- ---------------- ----------- -------
  1-min Apgar less than 7    5 (20.0)                        7 (29.2)         0.456       
  5-min Apgar less than 7    2 (8.0)                         2 (8.3)          0.999       
  NICU admission             21 (84)                         24 (100)         0.110       
  NICU admission (day)       33.88±38.61                     49.83±39.82      0.089       
  Adverse neonatal outcome   7 (28.0)                        14 (58.3)        0.032       
                             Death                           1 (4.0)          2 (51.1)    0.609
                             Respiratory distress syndrome   6 (24.0)         11 (45.8)   0.108
                             Intraventricular hemorrhage     1 (4.0)          3 (12.5)    0.349
                             Patent ductus arteriosis        1 (4.0)          3 (12.5)    0.349
                             Retinopathy of prematurity      4 (16.0)         4(16.7)     0.999
                             Necrotizing enterocolitis       4 (16.0)         4(16.7)     0.999
                             Sepsis                          0 (0.0)          3 (12.5)    0.110
  Mechanical ventilation     7 (28.0)                        14 (58.3)        0.032       

Data are presented as numbers (percentages) or means±standard deviations.

NICU, neonatal intensive care unit.

Discussion
==========

In our study, the use of a cervical pessary to shorten the cervix to \<15 mm was associated with prolongation of a twin pregnancy. This suggests that its use can effectively postpone delivery until a viable gestational age, especially in twin pregnancies. Two large randomized controlled trials (RCTs) examined the use of a cervical pessary in singleton pregnancy. The PECEP trial compared a pessary group (n=192) and an expectant management group (n=193) with a CL of ≤25 mm. The rate of spontaneous delivery before 34 weeks of gestation was significantly lower in the pessary group (n=12; 6%) than in the expectant management group (n=51; 27%; *P*\<0.001) \[[@B16]\]. However, a multinational trial observed no significant difference in the rate of spontaneous early preterm delivery before 34 weeks between 465 women who underwent pessary placement (n=55; 12.0%) and 467 who did not (n =50; 10.8%; *P*=0.57) \[[@B17]\]. The use of a cervical pessary in twin pregnancy was studied in three RCTs \[[@B18][@B19][@B20]\], of which two demonstrated that its use was not associated with a reduction in preterm delivery among unselected twin pregnancies. In the ProTwin trial, the subgroup analysis for those with a CL of \<38 mm showed that the use of a pessary reduced the risk of preterm delivery before 28 weeks (n=3; 4%, in those who underwent pessary placement vs. n=9; 16%, in those who did not; *P*=0.0158) or 32 weeks (n=11; 14% vs. n=16; 29%; *P*=0.0476) \[[@B20]\]. The PECEP-Twins trial showed that a cervical pessary prevented preterm birth before 34 weeks in women with a twin pregnancy and a short cervix (CL of \<25 mm; pessary group, 12/68 \[17.6%\] vs. control group, 27/66 \[40.9%\]; *P*=0.002) \[[@B18]\]. Although a cervical pessary did not reduce the rate of preterm delivery in unselected twin pregnancies, these studies showed the potential value of prophylaxis against SPB in women with twin pregnancies and a very short cervix. Therefore, we began to investigate whether the use of a cervical pessary would help protect against SPB in twin pregnancies, similar to that with the use of cerclage or progesterone administration. Moreover, we found no study on the use of a cervical pessary in twin pregnancies in Korea. Unlike in previous trials, we selected and investigated women with twin pregnancies and an extremely short cervix (≤15 mm). We focused on patients at a high risk of SPB who needed immediate intervention. Hassan et al. reported that patients with a CL of ≤15 mm needed urgent intervention because of a 50% risk of SPB \[[@B21]\]. This study did not show that the use of a cervical pessary significantly reduced the rate of SPB compared with the controls but showed that its use could help prolong a pregnancy until viable gestational age in women with impending childbirth. The Arabin pessary is inexpensive, is relatively safe, and has few side effects. Half of the patients in the pessary group reported increased vaginal discharge; however, none requested pessary removal because of discomfort. Arabin et al. \[[@B13]\] reported that contraindications for the use of a pessary included lethal fetal abnormality, suspected chorioamnionitis, ballooning of membranes into the vagina, effective uterine contractions, and uterine anomalies, such as the presence of two cervices.

Although the gestational age at birth did not differ significantly between the groups, the birth weight in the pessary group tended to be higher than that in the control group. The use of a pessary reduced the rate of adverse neonatal outcomes and need for mechanical ventilation.

Our study had some strengths. All participants had a very short cervix (CL of ≤15 mm), and the same doctor performed all procedures, eliminating all procedure-related bias. In contrast with Europe, in Korea, cervical pessaries are not widely used to prevent SPB in women with twin pregnancies and a short cervix \[[@B22]\]. Our study may encourage further research on the use of a cervical pessary in Korea and other Asian countries. As limitations, this small retrospective study was performed in a medical center and did not consider cervical cerclage, IVF, chorionicity, or other unknown factors that might have influenced the outcomes. Our results raise several concerns: if pessaries can be used for prophylaxis after cervical conization or LEEP, if progesterone supplementation is effective after pessary insertion, and when outpatient follow-up should be performed after pessary insertion. Further research is needed to address these concerns in addition to ongoing research on the role of prior cerclage.

No reported interventions, to date, were effective in twin pregnancy \[[@B9][@B23]\] in contrast with singleton pregnancy; thus, it is necessary to consider alternative methods. The use of a cervical pessary may reduce the rates of SPB and adverse neonatal outcomes in twin pregnancy. When it is necessary to prolong gestation in a pre-viable twin pregnancy, a cervical pessary may be used. Thus, research on the use of a cervical pessary should continue.

In conclusion, the use of a cervical pessary may prolong gestation in women with twin pregnancy and an extremely short cervix until viable gestational age. The pessary group had fewer adverse neonatal outcomes than the control group. However, further large and well-designed trials are needed to verify our findings.
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